Dr. Eshan Patel, MD

Dr. Patel practices at Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey, part of RWJBarnabas Health.

Dr. Patel's NPI, 1770821498, was assigned on January 31, 2013. Dr. Patel holds New Jersey license 25MA09981300.

Dr. Patel's primary practice is Robert Wood Johnson University Hospital Somerset, at 110 Rehill Ave, Somerville, NJ 08876 in Somerset County. The practice phone is (908) 685-2200.

Dr. Patel's primary practice is Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey, part of RWJBarnabas Health. Dr. Patel is also affiliated with Robert Wood Johnson University Hospital. The medical group on file is RWJBarnabas Health Medical Group. Dmand AI also links Dr. Patel to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Patel practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Patel's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Patel's licenses on file in 2 states: New Jersey and New York.

CMS data shows 1,248 Medicare services from Dr. Patel across 6 procedure codes in 2024, for 392 Medicare patients. Medicare paid $101,655 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 392 Medicare patients who saw Dr. Patel in 2024. The largest group is 75 to 84, with 157 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Patel's median patient age at 72, with 53% women.

In 2024, Dr. Patel wrote 1,065 Medicare Part D claims for 198 patients. 70% of them were for generic drugs. CMS names the drug for 815 of them, across 25 drugs with 11 or more claims each, at $1,934,199 in total drug cost. In 2023, CMS named 525 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Patel for performance year 2024, reported through an alternative payment model (APM). Dr. Patel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Patel as offering telehealth.

Dmand AI links 121 papers to Dr. Patel, published from 2011 to 2025. 2021 was the busiest year, with 12. The most frequent topics are HIV Infections, COVID-19 and SARS-CoV-2. Dr. Patel has published most often in Clin Infect Dis. Dr. Patel's most frequent co-authors are Thomas C. Quinn, MD, Evan Martin Bloch, MD and Ruchika Goel, MD, MPH.

Dmand AI links Dr. Patel to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Mantle-Cell. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 664 general payments to Dr. Patel from 34 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Janssen Pharmaceuticals, Inc paid the most, $180,275.